EGFR and non-small cell lung carcinoma: This approval is based on the prespecified analysis of the OptiTROP-Lung03 study, a multicenter, randomized controlled trial evaluating the efficacy and safety of sacituzumab tirumotecan versus docetaxel in pretreated patients with EGFR-mutant advanced NSCLC.